BNTX BioNTech SE
Price Chart
Executive Summary
BioNTech announced new clinical data for pumitamig (Phase 2/3 ROSETTA Lung-02 in 1L NSCLC) and gotistobart (Phase 2 PRESERVE-004 in platinum-resistant ovarian cancer) to be presented at ASCO 2026. The data show encouraging anti-tumor activity and durable overall survival, supporting the company's late-stage oncology pipeline of 25+ Phase 2/3 trials including 13 pivotal studies. No financial figures, guidance, or regulatory decisions were disclosed.
Actionable Insight
Monitor ASCO 2026 presentations (May 29–June 2) for detailed efficacy/safety data on pumitamig and gotistobart. Positive data could drive near-term upside for BNTX, but no regulatory or commercial milestones are imminent. Watch for analyst reactions and potential partnership updates.
Key Facts
- Pumitamig (PD-L1 × VEGF-A bispecific) interim Phase 2 data from ROSETTA Lung-02 in 1L NSCLC shows encouraging anti-tumor activity across PD-L1 levels; third global dataset to show consistent activity.
- Gotistobart (anti-CTLA-4) Phase 2 PRESERVE-004 data in platinum-resistant ovarian cancer shows durable anti-tumor activity and clinically meaningful overall survival.
- BioNTech has 25+ Phase 2/3 trials, including 13 ongoing pivotal trials and novel-novel combination trials with ADCs.
- No revenue, EPS, guidance, or financial data were provided in the press release.
- Presentations at ASCO 2026 (May 29–June 2) include two oral presentations and four trial-in-progress posters.
Financial Impact
No financial figures disclosed; pipeline updates are non-financial catalysts.
Risk Factors
- Clinical data at ASCO may not meet expectations, leading to stock volatility.
- No financial guidance or revenue catalysts provided; pipeline remains early-stage with execution risk.
- Competition in NSCLC and ovarian cancer from established PD-1/CTLA-4 therapies and ADCs.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3299948 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 8, 2026
1d ago
|
6-K
| $88.08 awaiting T+5 | awaiting T+5 | — | $85.50 (−2.93%) |
|
Jun 1, 2026
8d ago
|
6-K
| $91.70 $88.08 | ▼ −3.95% | ▼ −1.20% | $85.50 (−6.76%) |
|
May 30, 2026
10d ago
|
Press Release
| $91.70 $88.08 | ▼ −3.95% | ▼ −1.20% | $85.50 (−6.76%) |
|
May 22, 2026
18d ago
|
6-K
| $92.14 $91.70 | ▼ −0.48% | ▼ −2.15% | $85.50 (−7.21%) |
|
May 22, 2026
18d ago
|
Press Release
| $92.14 $91.70 | ▼ −0.48% | ▼ −2.14% | $85.50 (−7.21%) |
|
May 15, 2026
25d ago
|
6-K
| $88.85 $92.25 | ▲ +3.83% | ▲ +2.21% | $85.50 (−3.77%) |
|
May 7, 2026
4w ago
|
6-K
| $93.02 $92.23 | ▼ −0.85% | ▼ −2.35% | $85.50 (−8.08%) |
|
May 5, 2026
5w ago
|
6-K
| $95.50 $93.66 | ▲ +1.93% | ▲ +3.91% | $85.50 (+10.47%) |
|
May 5, 2026
5w ago
|
6-K
| $95.50 $93.66 | ▼ −1.93% | ▼ −3.91% | $85.50 (−10.47%) |
|
May 5, 2026
5w ago
|
Press Release
| $95.50 $93.34 | ▼ −2.26% | ▼ −4.25% | $85.50 (−10.47%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access